
Avapro[®] (Irbesartan) in Type 2 Diabetic Renal Disease

Brian F. Daniels, M.D.

Vice President, Pharmaceutical Research Institute
Bristol-Myers Squibb

7 a s d f

sanofi~synthelabo

Agenda

- Introduction
- Disease Background
- Irbesartan Diabetic Nephropathy Trial
- IRbesartan MicroAlbuminuria in Type 2 Diabetic Subjects
- Benefit:Risk Assessment

Consultants

Julia A. Breyer Lewis, M.D.

Professor of Medicine, Vanderbilt University,
Nashville, TN

Lloyd D. Fisher, Ph.D.

Professor Emeritus, Biostatistics, University of Washington,
Kenmore, WA

Marc A. Pfeffer, M.D., Ph.D.

Professor of Medicine, Harvard Medical School
Cardiovascular Division, Brigham and Women's Hospital,
Co-Chief, Medical Service
VA Boston Healthcare System
Boston, MA

Avapro[®] Current Profile

- Avapro[®] is an angiotensin II receptor blocker
 - Antagonist of the AT₁ receptor subtype
- Current indication is for the treatment of hypertension
 - Now available in over 79 countries
 - Over 3.6 million patient-years experience worldwide
- Recommended starting dose of 150 mg once daily for hypertension: recommended maximum dose of 300 mg once daily

Avapro[®] Development Program in Type 2 Diabetic Renal Disease

- Irbesartan Diabetic Nephropathy Trial (IDNT)
 - Renoprotection in 1715 hypertensive patients with type 2 diabetic nephropathy (overt proteinuria)
- IRbesartan MicroAlbuminuria in type 2 diabetic subjects (IRMA 2)
 - Renoprotection in 590 hypertensive patients with type 2 diabetes and microalbuminuria

Avapro[®] Proposed Indication

Hypertension and Type 2 Diabetic Renal Disease

- Avapro[®] (irbesartan) is indicated for the treatment of type 2 diabetic renal disease